Screening is the identification of a preclinical disease by a relatively simple test. It is usually regarded as public health policy that is applied to population. The aim is to identify disease not recognized by the health services and the term preclinical refers rather to such an unrecognized disease than to clinical detectability or recognition. The majority of pigmented lesions of the skin can be diagnosed on the basis of clinical criteria, although there is an astonishing number of discrete pigmented lesions where the difference between melanocytic and non-melanocytic, benign and malignant lesions, melanoma and non-melanoma, is very hard or almost impossible to detect by a simple examination with the naked eye. With the use of the computer system for melanomoscopy and melanomography, Mole Max II, with digital epiluminescence microscopy, it is possible to see and record the changes on the skin that are located in the surface layer of the skin, as well as the changes that appear more deeply under the surface, on the border between the epidermis and the dermis, the place where melanocytes are placed. With such examination it is possible to differentiate benign from malignant lesions in the very early stage of the development. An early recognition of malignant alterations on the skin increases the chances of cure and total recovery to over 90%.